TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Concentrations of MDMA and metabolites (influence of gender)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of MDMA and metabolites (influence of genetics)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of HDL cholesterol efflux capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proteome alteration of HDL subclass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathologic Tumor Necrosis Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of participants achieving or maintaining MBL volume <80 mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VAS Pain and Patient Satisfaction Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV Viral Load Suppression in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HIV Viral Load Suppression in Semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean distance to the humeral head and catheter insertion point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with rSBA titres ≥ 8 and ≥ 128
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: rSBA geometric mean titre (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pertussis antigen-specific antibody GMCs in IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain Tolerance Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Childhood Depression Rating Scale-Revised scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of Preterm Delivery for 48 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Early sensation during the filling phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Bronchopulmonary Dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective assessment of the lower limb function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Objective assessment of the lower limb function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eligible women enrolled and randomized
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Progression at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Syncope Burden
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of Vaccine-induced CD8+ T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute Number of CD4+CD25+FoxP3+ Regulatory T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Type and Grade of Toxicity Incidents
Endpoint domain: Adverse events/effects
Primary endpoint: UPDRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PDQ-39
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Movement Assessment Battery for Children-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preparedness for Colorectal Cancer Surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with Grade >/= 2 oral mucositis/stomatitis in Sub-Study
Endpoint domain: Adverse events/effects
Primary endpoint: Cost of diarrhea
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the game-based intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the game-based intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Usability of the game-based intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total fat in percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean body mass in percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral adipose tissue in cm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Continuous blood pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Rhinovirus-associated Illness Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Protein in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: skin mapping for peripheral tanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: visual analogue scale for surface tanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: vitiligo extent score for marginal and perifollicular repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: patient's satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient global percent of his own improvement (0-100%)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean physician's global assessment for percent of improvement (0-100%)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Biomarkers expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Progression or Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Visual Scale Analogue (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total number of fixations during search
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of fixations during search
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed 100% of the Prescribed Exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-cycle dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: ECG QTc Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevention of Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: platelet aggregation defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Right ventricular end-diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin action and secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Quality of Life (WHOQOL-AGE)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent of neonatal survivors at time of discharge
Endpoint domain: Mortality/survival
Primary endpoint: PBAC Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of multiple joints osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of multiple joints osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression of multiple joints osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Positive Subjective Drug Effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent follow-up after medication abortion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Whole Body Insulin Sensitivity Measured by the Glucose Infusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole Body Lipid Turnover Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symbol Digit Modalities Test, Oral Version (SDMT) - Total # Correct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subject's Global Assessment of Cognitive Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent change in Eczema Area and Severity Index (EASI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: incidence of new hip fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Early and Late Innate Immune Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the Adaptive Immune Response and Cellular Recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Liver histological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of the symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement Rate for Low Density Lipoprotein-Cholesterol (LDL-C) for Overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement Rate for LDL-C by Dose Group Within Each Cardiovascular Disease (CVD) Risk Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: event-free survival after allogeneic HSCT
Endpoint domain: Mortality/survival
Primary endpoint: overall survival after allogeneic HSCT
Endpoint domain: Mortality/survival
Primary endpoint: occurrence of acute and chronic Graft-versus-Host-Disease (GvHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Function of blood circulating dendritic cells (DC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visualization rates of the ampulla of Vater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration curve (AUC) of ODM-203
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t) of etanercept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients admitted with adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: sUA < 6.0 mg/dl at 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urticaria symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VDT learning Change Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of plasma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of New FLAIR Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Saving Inventory-Revised (SI-R) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Remain in the Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Genetic profile at disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical success after pulpotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical success after indirect pulp cap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographic success after pulpotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Change in Mean Mouth and Throat Soreness (MTS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of women requiring pharmacotherapy for glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean daily glucose levels after 2 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time with low CGM values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radial artery stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) Percent (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delivery outcomes in preterm-preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Pain control satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vitamin D concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of the knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: fusion status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: device retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maintenance of segmental lordosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of (Serious) Adverse Events ((S)AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Vital signs (body temperature, heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy Improvement in Ultrasound Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of Hip Implant Based on Number of Hips Requiring Revision
Endpoint domain: Mortality/survival
Primary endpoint: Survival of Hip Implant Based on Time Until Revision Required
Endpoint domain: Mortality/survival
Primary endpoint: Clinical laboratory variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiograms and telemetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessments of anxiety and mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mean Effective Dose (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of CT Scans With an Effective Dose Above Benchmark
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent and intensity of physical activity between pregnancy week 9 and 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent and intensity of physical activity between pregnancy week 23 and 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent and intensity of physical activity between pregnancy week 36 and 39
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of repeatable spirometry tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sexual function of pelvic floor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ocular Surface Disease Index questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SAFETY, number of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Disease control (DC) according to RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of nephrocalcinosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage difference in LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients consenting to the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients withdrawing after consent
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immune-related Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peritoneal fluid cytokine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-care levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: quadriceps isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain or discomfort threshold volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative radioactivity excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awake time
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Average mood symptom score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fecal shedding of type 2 Sabin virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of Subjects Achieving LODS Total Score ≤ 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of balloon position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cancerous lesions and polyps detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maintenance of spinal alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change From Baseline in Corneal Staining at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessment of MEDI-507
Endpoint domain: Adverse events/effects
Primary endpoint: near-miss sudden death
Endpoint domain: Mortality/survival
Primary endpoint: sustained VT requiring defibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vessel diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of Chemotherapy + Filgrastim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: compliance with Mandibular Advancement Device
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stability of HNPS ranking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Had Adequate Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Oxygen Desaturation Less Than 95%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage Change From Baseline in the LDL-C/HDL-C Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Device success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Limits of Stability Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet-Leukocyte Aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in plasma PlGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in urine LT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of surgery time in hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-Normalized Area Under Curve (AUC) of Physician Global Assessment (PGA) of Psoriasis Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hull Airway Reflux Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: development of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of Participants With COVID-19-Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Participants With Rehospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of Participants With Major Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preceptor Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing